阿立哌唑与舒必利治疗老年人精神分裂症的对照研究

Control study on aripiprazole and sulpiride in treatment of elderly schizophrenic patients

目的:比较阿立哌唑(澳哌)与舒必利治疗患有精神分裂症的老年患者的疗效和安全性。方法:对符合CCMD-3精神分裂症诊断标准,年龄>60岁、阳性和阴性症状量表(PANSS)≥76分的精神分裂症的老年患者69例,根据随机对照方案分别使用阿立哌唑(32例)和舒必利(37例)治疗,疗程均为6周。在入组前和治疗后2、4、6周末,用PANSS量表评定疗效,用药物副反应量表(TESS)评定不良反应。结果:经PANSS评定,两组治疗后6周与治疗前比较在统计学上无显著性差异(P>0.05)。经TESS量表评定,两组间总不良反应比较,阿立哌唑组少于舒必利组,在统计学上有显著性差异(P<0.05)。结论:阿立哌唑治疗老年人精神分裂症有良好疗效,不良反应小而安全。

Objective ： To compare curative effects and safety of aripiprazole and sulpiride in treatment of elderly schizophrenic patients. Methods ：69 elderly schizophrenic patients meeting the diagnostic criterion of CCMD -3 schizophrenia and with ages of over 60 years old and positive and negative symptoms scale （PANSS） of over 76 points were selected and randomly divided into two groups, wherein 32 cases were treated by aripiprazole for 6 weeks and 37 cases were treated by sulpiride for 6 weeks. Before and 2, 4, and 6 weeks after the treatment, the curative effects were evaluated by PANSS, and adverse reactions were assessed by treatment emergent symptom scale （TESS）. Results ： There were no significant differences for the two groups in PANSS before and 6 weeks after the treat- ment （P 〉 0. 05）. However, the adverse reactions assessed by TESS of aripiprazole group were less than those of sulpiride group, and there was a statistical significance （ P 〈 0.05 ）. Conclusions ： Aripiprazole has a good curative effect for treating elderly schizophrenia and fewer side reactions, and also is safe.